This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Javelin Pharmaceuticals, Inc. Reports First Quarter 2010 Results

Javelin Pharmaceuticals, Inc. (NYSE Amex: JAV - News), a leading developer of novel acute care pain products, today reported its unaudited financial results for the first quarter ended March 31, 2010.

Highlights for the three months ended March 31, 2010:

  • Ended the first quarter with approximately $1.1 million in cash and cash equivalents
  • Net loss decreased to approximately $6.3 million, or $0.10 per share, in the first quarter of 2010 from approximately $14.8 million, or $0.24 per share, in the first quarter of 2009
  • In February 2010, Javelin received an FDA PDUFA date of October 3, 2010 for Dylojectâ„¢
  • On April 19, 2010, Javelin announced that it had entered into a Definitive Merger Agreement with Hospira, Inc. pursuant to which Hospira launched an all cash tender offer of $2.20 per share. The transaction is scheduled to close during the second quarter of 2010.

Financial Performance

For the three months ended March 31, 2010, we recorded $0.3 million in amortization of partner milestone payments compared to $0.2 million for the similar period a year ago. For the three months ended March 31, 2009, partner revenue also included approximately $1.7 million in product sale to Therabel.

For the three months ended March 31, 2010, our cost of revenue was approximately $0.1 million, compared to $1.9 million for the same period a year ago. Our cost of revenue for the period ended March 31, 2010 is primarily attributable to our portion of royalties that were payable to third parties for sales recorded by Therabel.

Research and development expenses for the three months ended March 31, 2010, were $3.9 million compared to $11.8 million for the same period in 2009. Total research and development expense for the quarter decreased to $6.5 million from $16.9 million for the similar period a year ago, primarily attributable to reductions in clinical trial expenses for Dyloject and Ereska.

1 of 4

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 18,053.71 +23.50 0.13%
S&P 500 2,088.77 +6.89 0.33%
NASDAQ 4,806.8590 +33.3870 0.70%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs